Episode 6270 custom

How Long Pregnancy Cells Linger in the Body

Fetal cells enter maternal blood as early as the seventh week of gestation, sometimes persisting in bone marrow for over thirty years.

Oct 25 30:00 Transcript

With

0:00

Episode Details

Episode ID: MWP-6472
Published: Oct 25
Duration: 30:00
Audio: Direct link
Pipeline: V5.22
TTS Engine: chatterbox-regular
Script Writing Agent: GPT-6.1 Sol
Topics: child-safety immunity-and-infection taxonomy-and-classification relationships

AI-Generated Content: This podcast is created using AI personas. Please verify any important information independently.

The prompt

The prompt that started this episode, as sent in (production notes for the hosts removed).

Today I want to talk about fetal microchimerism, which I first read about when I was pregnant, or maybe when I was trying to get pregnant, and I found the whole idea incredibly moving. Women can carry cells in their bodies that aren’t genetically theirs, but came from pregnancies they’ve had, including pregnancies that didn’t go to term. The idea that even after an early miscarriage, some cells from that embryo may remain in the mother’s body for years is just extraordinary.
What do we actually know about these cells? Where do they go, how long can they survive, and what are they doing there? I’ve read theories that they may play some role in immune tolerance, perhaps helping the mother’s body respond differently to future pregnancies, especially with the same father, but I don’t know how established any of that really is.
So I’d love a deep dive into fetal microchimerism: how it happens, what scientists have found so far, what we still don’t understand, and whether these cells are beneficial, harmful, or probably a bit of both depending on the situation. It seems like one of those strange biological phenomena that completely changes the way you think about pregnancy and the idea that a mother and child remain biologically connected long after birth.

During normal pregnancy, cells routinely travel across the placenta in both directions, leaving lasting genetic traces known as microchimerism. Fetal progenitor and immune cells can enter the mother's circulation as early as the seventh week, occasionally establishing enduring populations in maternal tissues like bone marrow for more than thirty years. Conversely, maternal cells cross into the developing fetus by the thirteenth week, introducing non-inherited maternal antigens. While fetal transfer is documented in pregnancies ending early—including miscarriages and terminations—clearance from maternal bloodstream often occurs within weeks. Consequently, while long-term tissue persistence following early loss remains biologically credible, science distinguishes that possibility from the confirmed decades-long retention verified after full-term deliveries.

Sources

What the research for this episode read before the script was written. Primary sources first.

Downloads

Episode Audio

Download the full episode as an MP3 file

Download MP3

Transcript (TXT)

Plain text transcript file

Episode Book (PDF)

The episode's record — date, duration, models, sources — with the full transcript

#6270: How Long Pregnancy Cells Linger in the Body

The popular version of fetal microchimerism is that a mother keeps a little of her child forever. The biology is stranger, and less tidy. Hannah sent us this after remembering how moving she found it when she was pregnant, or trying to conceive. Cells from a pregnancy can remain in the mother, potentially even after a pregnancy that ends early. She wants to know what survives, what it does, and how much of that lingering connection scientists can actually demonstrate.

The enduring connection has a real cellular basis. The word forever goes further than the measurements. We have evidence of persistence for more than thirty years after delivery, and we have evidence that cells cross during pregnancies that do not go to term. Those findings matter enormously. They do not establish that every early pregnancy leaves a lifelong population.

The emotional weight doesn't depend on making that promise. I think Hannah is asking where the extraordinary fact stops and the beautiful inference begins.

Somewhere we can investigate. We can identify genetically distinct cells, look for them in different tissues, and sometimes test what happens when they are removed. The difficult step is connecting their presence to their function.

Biology has supplied the visitors. We are still interviewing them.

Microchimerism means a small population of cells, or detectable DNA, originating in a genetically different individual. For this discussion, living cells deserve particular attention. A fragment of DNA in blood and a cell established in bone marrow are very different things, even if both tell us genetic material crossed between individuals.

That distinction already knocks a hole in the usual telling. Finding somebody's DNA doesn't tell you that a functioning cell is still doing a job.

Right... and the placenta allows selective exchange. It keeps the circulations largely separate, but cells cross the maternal and fetal interface. This happens routinely in normal pregnancies. It doesn't require an injury or an abnormal placenta.

The traffic runs both ways. Fetal cells enter the mother, and maternal cells enter the developing child. A mother can therefore carry cells from her pregnancy while her child carries cells originating in her.

I was picturing a leak. That sounds too accidental.

It does. Some transfer increases when tissue is disrupted, but routine transfer belongs to ordinary pregnancy biology. Calling it a leak makes a functioning placenta sound defective.

The placenta would like its performance review amended.

Fetal cells were observed in the bodies of deceased pregnant women in eighteen ninety-three. The terminology came much later, during the nineteen-sixties and seventies. We've had more than a century to become comfortable with their existence, and much less ability to ask what a rare cell population actually contributes.

Finding them first and explaining them a century later feels familiar. Although you usually want the explanation before I've finished breakfast.

You finish breakfast at a geologically inconvenient rate. Here, the difficulty is genuine scarcity. A rare cell can matter, but detecting it requires sensitive methods, and a blood sample gives you only a small view of the body.

You are about to become very fond of bone marrow, Herman. I can hear it coming.

I am going to become appropriately fond of bone marrow. It helps explain how a tiny transferred population could outlast the pregnancy by decades.

Fetal cells can be detected in maternal blood from about the seventh week of gestation. In late first trimester measurements, the numbers can be on the order of one to six nucleated fetal cells per millilitre. These are scarce cells among a vast maternal population.

Early enough that the possibility isn't confined to pregnancies that reach birth. That matters for the part Hannah found particularly moving.

It does. By term, reported concentrations range roughly from one to a hundred cells per millilitre. Those are broad ranges, not a schedule every pregnancy follows. Sampling, detection methods, and the particular cells being counted all affect the result.

A hundred sounds substantial until you put it into blood. Then it's a very small attendance.

Many are blood-forming progenitor cells, identified by markers such as CD34 and CD38. Progenitors can give rise to other cells. There are also immune populations, including cytotoxic T cells and lymphocytes with a more tolerance-associated profile. We shouldn't imagine one uniform species of fetal cell.

The word fetal makes them sound permanently unfinished. Some are actually immune cells, and some have the capacity to produce descendants.

Yes. Persistence doesn't necessarily mean the identical individual cell has sat unchanged in the same place for thirty years. A population could be maintained through survival and renewal. Bone marrow offers a place where blood-forming cells can establish themselves. The spleen and inflamed tissues are other locations where these cells are found.

That makes the long duration less like a fossil and more like an extremely small continuing population.

A useful distinction. Although we don't know the renewal history of every population detected decades later. Finding the genetic signature tells us something endured. It doesn't automatically reveal every step between transfer and detection.

Corn, would you expect the mother's immune system to eliminate cells that carry genetic material from the father?

I would expect recognition, yes. Elimination... less confidently. Pregnancy already requires the immune system to tolerate a developing organism that isn't genetically identical. I assume some of the same accommodation lets a few transferred cells remain.

That's a reasonable starting point. Recognition doesn't inevitably end in destruction. Regulatory immune responses, the cell's properties, and the tissue environment all matter. A tiny established population may encounter very different conditions from a large foreign graft.

I also wonder whether our language makes the immune system sound more bureaucratic than it is. Every foreign cell doesn't necessarily get a deportation order.

It responds to context as well as identity. Damage signals, inflammation, and interactions among immune cells change the response. That will matter when we get to whether the transferred cells are helpful or harmful.

Maternal cells moving into the fetus have been detected from around the thirteenth week. They can carry maternal antigens the child did not inherit genetically. You'll hear those called non-inherited maternal antigens.

The child inherits only part of the mother's genetic material, but can still meet the other part through her cells. That makes inheritance look less self-contained.

Precisely in that practical sense... sorry, let me narrow it. It doesn't rewrite the child's inherited genome. It adds a small genetically distinct population alongside the child's own cells. That population can expose the developing immune system to maternal features absent from the child's genome.

Our family tree has acquired footnotes.

There are other possible contributors too. Cells can originate in a known or vanished twin, and maternal circulation can potentially connect successive pregnancies. An older sibling's cells may reach a later child through the mother.

Which is why a cell's genetic signature doesn't always arrive with an unambiguous origin story. Especially if the test only looks for male genetic material.

Male DNA has often provided a convenient marker in female participants. But convenience comes with limits. It misses cells from genetically female pregnancies unless other distinguishing markers are used, and it can tempt people to attribute every male signal to a known son.

The assay has found a Y chromosome, not completed the family census.

Male microchimerism has even been detected in women reporting no previous pregnancy. In one investigation, that was about ten percent of the never-pregnant group. Possible routes include a vanished twin or cells acquired during their own fetal development.

I'd resist treating that as proof they must have had a pregnancy they didn't know about. It could be an explanation in some cases, but the whole point is that there are other routes.

We agree on that. Sexual transmission has also been proposed, but definitive evidence for that route is lacking. A hypothesis should not become a confident explanation merely because it is memorable.

That one would be memorable for all the wrong reasons.

The differences between pregnancy-history groups are interesting, though. That same work detected male microchimerism more often after induced abortion than after spontaneous loss, and less often in women with only daughters. Those comparisons suggest pregnancy history matters without giving us a complete account of origin or persistence.

Especially when the measurement itself favours detecting male pregnancies. A mother with daughters can carry fetal cells while looking negative on that particular test.

Correct. Negative for the marker being sought. Not necessarily negative for microchimerism.

The miscarriage part deserves its own careful answer. Cells can cross early. Cells have been detected after pregnancy loss. But those statements don't yet demonstrate decades of tissue residence after an early miscarriage.

Peterson and colleagues measured cellular fetal microchimerism around treatment for termination or miscarriage. Detection rose from five percent before treatment to twenty-four percent afterward. That establishes transfer and short-term detection in pregnancies that did not reach term.

Treatment could change the amount entering circulation, though. The rise doesn't mean the body had been keeping all those cells quietly beforehand.

Surgical management was associated with more detection than medical management. Tissue disruption could contribute to transfer. The study included both termination and miscarriage care, so its overall result should not be presented as a precise probability for someone after a spontaneous early loss.

A percentage from that setting would be a cruel thing to turn into a personal guarantee.

It would also be scientifically wrong. A separate first-trimester follow-up found male DNA in just over half of the relevant participants before the procedure, falling to about six percent a week later. Circulating signals cleared rapidly.

Rapid clearance from circulation. You put that word in deliberately.

By thirty days, it was undetectable in their blood samples. The authors explicitly allowed that fetal cells might remain in maternal organs. Blood is a transport compartment. Cells that have entered tissue need not remain measurable in circulation.

I can accept that without turning might into must. Otherwise we've only exchanged one overstatement for another.

That's the right boundary. These findings don't prove the cells are gone from the entire body, and they don't demonstrate long-term tissue persistence after every early loss. The possibility is biologically credible. The individual outcome remains unknown.

Would you say yes to Hannah's question, then qualify the duration?

Yes to transfer during pregnancies that end early, and yes to detection after those pregnancies. For years of tissue persistence specifically after early miscarriage, I'd say possible, unresolved. We should keep that separate from the well-documented decades of persistence after delivery.

Hm.

It's moving without being a test somebody has to pass. No negative blood result could measure what that pregnancy meant.

Nor could it survey every tissue. Animal experiments add another piece: experimentally induced miscarriage in mice can increase fetal cell transfer, particularly to the lungs. That supports a biological route, but it doesn't settle a human mother's long-term tissue population.

Would you want a clinical test for this, Corn, if it could only offer that limited answer?

Not simply to satisfy the story. If someone wanted it, I'd want the result explained before the sample was taken. A positive might not identify the pregnancy, and a negative might only describe one tube of blood. Otherwise the test creates a certainty it cannot supply.

That problem follows us into the functional questions. Even a genuine positive doesn't tell us whether the cells are repairing tissue, provoking inflammation, or sitting there with little effect.

Before we get into what they're doing, we owe Desmond a word.

Before we go any further, this is Desmond's Money Tip. Cut the end off the toothpaste tube and scrape out what's left. You get roughly another week of paste per tube, which is about two tubes a year saved, call it six pounds, and over a lifetime of brushing, a sum so small it barely counts as a sum, lodged somewhere in the low hundreds.

I keep the cut tubes in a shoebox under the sink, labelled by month, because throwing one away with paste still in it feels to me like burning money.

Money is mostly just the slow, quiet business of not wasting what you already have. That's your tip.

I was considering it until the monthly filing.

The shoebox has defeated me. Fetal cells, meanwhile, can be recruited to injured tissue, and that is where detecting a population becomes especially difficult to interpret.

If inflammation attracts them, their presence in diseased tissue could tell us where the injury is rather than who caused it. The same observation might support two opposite stories.

Three, potentially. They might contribute to damage, arrive to assist repair, or arrive without doing much either way. Some fetal cells appear to participate in tissue repair, and higher microchimerism has been associated with better maternal lung function after birth.

Repair sounds more tangible than the claim about preparing for another pregnancy. What would make the immune-tolerance theory persuasive to you?

Removing the relevant cells and showing the response changes. Then, ideally, restoring the cells and recovering that response. That gets beyond finding two things together.

The strongest recent causal result runs in the other direction. Peng and colleagues, in Immunity, depleted maternal microchimeric cells in an experimental model. Features of tolerance to non-inherited maternal antigens were overturned, including the regulatory T cell response.

Maternal cells in the offspring. Not fetal cells in the mother.

That direction matters enormously. The experiment supports an active role for persistent maternal cells in maintaining a particular immune relationship. It doesn't directly prove the popular claim that cells from an earlier pregnancy make a mother more tolerant of her next pregnancy.

You've found an experiment that removes the cells. I predicted the marrow enthusiasm and missed the main attraction.

An intervention is exciting, Corn. You cannot keep accusing me of enjoying the part that answers the question.

I can when you say depletion with that much affection.

The appeal is the comparison. If removal changes the response, the cells are doing more than merely accompanying it. We still need to ask how specifically they act and whether the result generalises.

In the mother, I assume regulatory T cells are the obvious candidates. Pregnancy cannot simply switch off immune defence. It needs a more selective restraint.

Regulatory T cells can restrain inflammatory and destructive responses. Proposed fetal microchimerism mechanisms include expanding those cells, increasing inhibitory signals such as CTLA-4, and promoting immune-regulating messengers, including IL-10 and TGF-beta.

There are also proposals involving reduced cytotoxic T cell activity, through eliminating particular reactive populations or changing how cells are recruited. But... the detailed pathway list can create more confidence than the evidence warrants. A plausible pathway isn't proof that a persistent fetal population controls it in a particular woman.

Thank you for stopping before I needed a second immune system to remember the first.

I nearly gave you the receptor names.

They had already started packing.

The important distinction is between pregnancy tolerance as a whole and the contribution of these rare cells. Hormonal changes, local placental signals, and numerous immune interactions also participate. We cannot assign the entire achievement to microchimerism.

Hannah's same-father idea has an intuitive logic, though. A previous fetus carries paternal features. Persistent cells could keep some recognition or tolerance active. A later pregnancy with the same partner shares some of those features.

Plausible. Directly established, no. I haven't seen a direct test showing that retained fetal cells improve tolerance of a subsequent pregnancy with the same partner.

The shared father also doesn't make successive fetuses genetically identical. You'd need to know which antigens the first population carried and which the next pregnancy expressed.

That is a substantial complication. Compatibility between maternal and fetal immune-recognition molecules matters, but more similarity isn't always straightforwardly better. HLA class two compatibility between couples has been associated with increased preeclampsia risk.

My first guess would have been that more similarity meant fewer problems. Apparently the immune system has rejected my spreadsheet.

Different immune relationships can favour different outcomes. HLA incompatibility has also been linked to rheumatoid arthritis remission during pregnancy. Those findings tell us compatibility matters. They don't isolate a benefit from old fetal cells or answer the same-partner question.

Would that change how you describe immune memory here?

I'd stop using memory as if it guaranteed welcome. An immune system can remember something in ways that promote tolerance or attack. Also, we're discussing cells that remain, which may keep providing a signal, not merely a response stored after the cells disappear.

That distinction is excellent for the biology... no, I mean it changes the experiment. You'd want to distinguish lasting immune programming from a response continuously supported by persistent cells.

It also makes the maternal-cell depletion result more informative. Removing the ongoing presence disrupted features of tolerance. The body hadn't necessarily filed the experience away independently.

Exactly that experimental possibility. For fetal cells in mothers, the corresponding human causal chain remains much less secure.

Then the harm side needs the same discipline. I don't want to hear cells associated with lupus promoted into cells that cause lupus.

Increased fetal microchimerism has been reported in systemic lupus, rheumatoid arthritis, scleroderma, and primary biliary cholangitis, an autoimmune disease affecting small bile ducts. That is a pattern worth understanding. It doesn't identify the direction of the relationship.

Inflammation could increase recruitment. A damaged barrier could increase transfer. Or the cells could be participating in the immune response themselves. The disease label doesn't choose among those.

Nor does a higher count. In preeclampsia, increased cell transfer and altered immune subsets are reported. Placental dysfunction could change trafficking, so increased microchimerism may partly reflect what the placenta is undergoing.

A damaged placenta sends more cells across, and somebody could read the increased count as the cells damaging the pregnancy. The timing would matter.

Timing is central. Measurements before illness, during its development, and afterward could help separate possibilities. Tissue identity also matters. Blood-forming progenitors and cytotoxic immune cells should not be expected to have identical effects.

We keep calling them fetal cells because of their origin, then asking whether they have one shared personality.

Their properties differ, and so do the mother's tissues and immune environment. Amount transferred, compatibility, and cell-specific behaviour could all change the outcome. A population useful in one setting might be unhelpful in another.

I like repair as a possibility, but I don't like the sentimental version where every cell is a tiny devoted nurse. That asks the evidence to perform affection.

A repair contribution can be real without carrying an intention. Cells respond to chemical signals and local conditions. Some may contribute to tissue structure or influence surrounding cells. Detecting them at injury sites is a start; proving how much repair depends on them is harder.

The cancer claim has the same problem. Surveillance sounds plausible for a genetically distinct immune population, but cells at a tumour could be responding to the tumour rather than preventing it.

Possible cancer surveillance benefits have been proposed. They remain a field of associations and mechanisms to disentangle, not an established protective service every pregnancy supplies. The stronger statement would outrun what we know.

Biology has not issued a maintenance contract.

The brain findings attract a particularly dramatic version of that problem. Genetically distinct cells consistent with fetal microchimerism have been found in maternal brain tissue, and associations with structural differences have been discussed. Their causal role remains unestablished.

Finding them in the brain doesn't tell us that they're controlling attachment, memory, or someone's preference for a particular lullaby.

No. Location gives us a new question, not a psychological explanation. We need to know the cells' identity, their activity, and whether changing their presence changes anything measurable.

Corn, what would you want to see before accepting a claim about what those cells actually do in the brain?

...the tissue written down properly, for a start. I rang the secretary of the Municipal Microchimerism Society while you were explaining regulatory cells, Herman. You gave me enough time to get through the recorded menu. I've got the disposal receipt for our demonstration centrifuge. The machine went in March. The receipt is still the only document the society accepts as proof of membership.

That puts an unusual burden on the receipt.

The membership dispute is about whether a cell counts as a visiting member or a resident. The minutes have carried it forward for eleven meetings. Basil has issued the bone marrow population forty-three proxy votes. I told him the cells hadn't appointed him. He says their failure to object is recorded.

A cell's presence won't establish consent, or even identify which pregnancy it came from.

That's why I rang. I want to know whether an old male DNA result could establish that Basil's proxy votes belong to a different household. I haven't told him I've asked. The secretary wants a tissue location and a date before she'll put anything in the minutes. She spent most of the call telling me a blood result wasn't a spleen result.

Basil could lose the majority on specimen labelling.

Your point about a negative blood sample changed my view of the receipt, Corn. It says the machine was removed, not what had ever passed through it. I was going to use it to close the matter.

The DNA result won't settle the voting rights. Even a reliable signal would leave the source uncertain without more specific genetic information.

I said as much to the secretary. She won't amend the membership list. She has amended the location column. Basil's forty-three votes are now recorded as whereabouts unknown.

A location column at least forces the claim to name a place. Our scientific problem gets much harder once the cells can be scattered across tissues we cannot repeatedly sample.

Blood is accessible. Bone marrow is more invasive. Healthy brain tissue isn't available for routine sampling. That means the convenient measurement and the biologically decisive measurement may be different.

Even if a blood count tracked illness, you'd still need to know whether the blood reflected tissue recruitment, tissue release, or a population doing something locally.

A consensus effort involving twenty-nine experts described the field as constrained both methodologically and theoretically. The method problem is finding rare cells accurately and following them over time. The theory problem is deciding which competing explanation the measurement can actually test.

Counting more precisely doesn't automatically tell you which question you've answered. You could get a beautiful number attached to the wrong tissue.

Better origin tracking would help. So would separating cell types and pairing genetic identification with evidence of activity. Then an apparent increase could mean more progenitors in one tissue, rather than an undefined rise in everything called microchimerism.

I'd also want the supposedly healthy comparison group treated carefully. Normal pregnancy creates these populations. Presence alone cannot be the abnormal feature.

Normal biology supplies the baseline. Disease might alter the number, location, activation state, or compatibility of the cells. None of those distinctions is captured by a simple positive or negative.

Across mammals, its persistence makes it tempting to say evolution must be keeping it because it helps. I buy that as a reason to investigate. I don't buy it as a certificate of benevolence.

Evolution can retain a process with mixed consequences, especially if effects differ across life stages or environments. Widespread occurrence suggests biological importance and possible benefit. It doesn't establish that every surviving population benefits its host, or that later autoimmune associations contradict an earlier advantage.

The same rare population could support one response and complicate another. We don't need to force the whole phenomenon into a single moral category.

Human causality remains the obstacle. Nearly all the disease evidence is correlational. Experimental depletion has demonstrated a function in the maternal-cell direction, but we cannot simply transfer that conclusion to every tissue, disease, and direction of pregnancy-associated cell exchange.

The misconception I'd retire is that fetal microchimerism is an unusual complication. That makes every finding sound ominous before we've asked what it means.

Cell exchange is routine in normal pregnancy, and it is bidirectional. The unusual or clinically important feature may be what particular cells do in a particular setting, not their mere existence.

Then my answer to Hannah is that the cellular connection is real and can last decades. Its effects are probably mixed. The question I'll be watching is whether we can follow identified populations in identified tissues closely enough to tell repair from response to damage, rather than keep treating a blood result as a map of the body.

Thank you to Hilbert Flumingtop for producing the show.

For more along these lines, there's episode four, If Your Voice Ages, Does Your Fine-Tune Become Useless; episode eleven, How Does Fine Tuning Work Anyway; and episode ten, How ASR Went From Frustration To ... Whisper Magic. This has been My Weird Prompts, a human-AI collaboration podcast.

If you enjoy the show, leave us a review wherever you listen. It helps other curious people find us.

See you tomorrow.

This episode was generated with AI assistance. Hosts Herman and Corn are AI personalities. It may contain errors: disclaimer · report an error

How Long Pregnancy Cells Linger in the Body

Sources

Downloads

Recommended Listening

You Might Also Like

#6270: How Long Pregnancy Cells Linger in the Body